烏龍製藥 URGN 深 滬
等待開盤 11-26 09:30:00 美东时间
27.69
+0.760
+2.82%
華盛通- 最 高27.98
- 今 開26.94
- 成交量 65.30万股
- 最 低 26.70
- 昨 收 26.93
- 總市值 12.81亿
- 52周最高 27.98
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 3.42
- 委 比 97.99%
- 總股本 4626.41万
- 歷史最高 69.568
- 量 比 0.49
- 振 幅 4.75%
- 歷史最低 3.42
- 每 手 1
- 風險率 4.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
UroGen Pharma Ltd., a biotech company focused on developing innovative treatments for urothelial and specialty cancers, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2-4, 2025, in New York, NY. The company will host a fireside chat on December 2, 2025, at 1:00 PM ET. Webcast links and replays will be available on UroGen’s Investor Relations website for 90 days. UroGen specializes in creating sustai...
11-25 13:00
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
Urogen Pharma ( ($URGN) ) has released its Q3 earnings. Here is a breakdown of ...
11-07 13:54
UroGen Pharma Q3 EPS $(0.69), Inline, Sales $27.500M Miss $33.093M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.69) per share which met the analyst consensus estimate. This is a 25.45 percent decrease over losses of $(0.55) per share from the same period last year. The
11-06 21:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Pharma reported Q3 2025 financial results, highlighting strong performance of ZUSDURI with $1.8M net revenue and a $4.5M demand estimate in October. JELMYTO contributed $25.7M revenue, up 13% YoY. UGN-103 showed a 77.8% complete response rate, aligning with ENVISION results, with FDA agreement on NDA submission. Cash reserves stood at $127.4M. A conference call was scheduled for further updates.
11-06 13:00
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma Ltd. announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 11, 2025, in Boston, featuring a presentation and investor meetings. The company, focused on innovative treatments for urothelial and specialty cancers, will also provide a webcast available on its Investor Relations website for 90 days.
11-04 13:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $40 price target.
10-27 23:22
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
UroGen Pharma announced that the CMS has assigned a permanent HCPCS Level II J Code, J9282, for ZUSDURI (mitomycin) for intravesical solution, the first and only FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The J Code, effective January 1, 2026, aims to streamline billing and claims submission across care settings, simplifying reimbursement processes for providers and improving...
10-27 12:00
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
